Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annovis Bio, Inc.ANVS · Entity 7001 | Director | May 20, 2026 | May 22, 2026 |
| Embark Technology, Inc.NGAB.U · Entity 110807 | President | January 12, 2021 | January 13, 2021 |
| Northern Genesis Acquisition Corp.NGA.U · Entity 139591 | President | August 17, 2020 | August 17, 2020 |
| Northern Genesis Acquisition Corp. IIINGC.U · Entity 140918 | President | March 23, 2021 | March 24, 2021 |
| Translational Development Acquisition Corp.TDAC · Entity 6290 | Director · Chairman and CEO | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annovis Bio, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,364,883 |
Ending reported balance
After 2026-05-20 transaction · row 4
3 source rows · reconciled sequenceRow 1 · 2026-05-20 · Purchase · Acquired 2,562 · Balance 3,291,101 Row 3 · 2026-05-20 · Purchase · Acquired 18,849 · Balance 3,309,950 Row 4 · 2026-05-20 · Purchase · Acquired 54,933 · Balance 3,364,883 |
| Common StockSEC Table I · non-derivative | IndirectThe 2024 Hoffman Family Trust | 223,357 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 223,357 F1: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
Embark Technology, Inc.
Report date January 12, 2021 · Filed January 13, 2021
This filing explicitly reported no securities owned.
Northern Genesis Acquisition Corp.
Report date August 17, 2020 · Filed August 17, 2020
This filing explicitly reported no securities owned.
Northern Genesis Acquisition Corp. III
Report date March 23, 2021 · Filed March 24, 2021
This filing explicitly reported no securities owned.
Translational Development Acquisition Corp.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 53,395 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 53,395 · Balance 53,395 F2: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.71 to $0.9997, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth in this footnote. For reference, aggregate proceeds were $42,280.50 and the exact weighted average price was $0.7918438056. F1: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC") |
Filing footnotes · ownership attribution and instrument terms
F1: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC")
F2: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.71 to $0.9997, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth in this footnote. For reference, aggregate proceeds were $42,280.50 and the exact weighted average price was $0.7918438056.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Traws Pharma, Inc.
Report date August 27, 2020 · Filed August 31, 2020
Section 16 reporting ended · disclosed 2020-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Michael and Jane Hoffman 2013 Descendants Trust | 21,919 |
Reported balance
After 2020-08-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-08-27 · Sale · Disposed 182,492 · Balance 21,919 F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-27 transaction · row 2
1 source rowRow 2 · 2020-08-27 · Sale · Disposed 1,876 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy the Michael and Jane Hoffman 2013 Descendants Trust(Non-GST Exempt Trust) | 564 |
Reported balance
Holding disclosure · report date 2020-08-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 564 F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 20:05 UTC | Translational Development Acquisition Corp. TDAC · Entity 6290 | PurchaseWarrants · Derivative | 53,395 | $0.79 Strike: $11.50 | $42,278.16 |
DisclosureSEC source: 0001104659-26-068236 · tm2616067-1_4seq1.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,395 Underlying: Class A ordinary shares · 53,395 shares Expires not disclosed F2 · price: The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.71 to $0.9997, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of warrants purchased at each separate price within the range set forth in this footnote. For reference, aggregate proceeds were $42,280.50 and the exact weighted average price was $0.7918438056. F1 · derivative.exercise_date: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC") F1 · derivative.expiration_date: Each warrant becomes exercisable 30 days after completion of the Issuer's initial business combination, as described in the Issuer's filings with the Securities and Exchange Commission. The warrants expire five years after completion of the Issuer's initial business combination, or earlier upon redemption or liquidation, as described in the Issuer's filings with the Securities and Exchange Commission (the "SEC") Read SEC document |
| May 20, 2026 Filed May 22, 2026 00:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 54,933 | $1.90 | $104,367.21 |
DisclosureSEC source: 0001104659-26-065311 · tm2615429-1_4seq1.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,364,883 Read SEC document |
| May 20, 2026 Filed May 22, 2026 00:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 18,849 | $1.80 | $33,928.20 |
DisclosureSEC source: 0001104659-26-065311 · tm2615429-1_4seq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,309,950 Read SEC document |
| May 20, 2026 Filed May 22, 2026 00:11 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 2,562 | $1.75 | $4,483.50 |
DisclosureSEC source: 0001104659-26-065311 · tm2615429-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,291,101 Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 21:06 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 713,800 | $2.10 | $1,498,980.00 |
DisclosureSEC source: 0001104659-26-039675 · tm2611081-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,288,539 Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 01:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 15,000 | $4.24 | $63,600.00 |
DisclosureSEC source: 0001104659-25-119407 · tm2533031-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,574,739 Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 01:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 30,000 | $4.34 | $130,194.00 |
DisclosureSEC source: 0001104659-25-119407 · tm2533031-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,559,739 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:59 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 28,096 | $4.15 | $116,598.40 |
DisclosureSEC source: 0001104659-25-116084 · tm2532217-1_4aseq1.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,529,739 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:59 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 415 | $4.14 | $1,718.10 |
DisclosureSEC source: 0001104659-25-116084 · tm2532217-1_4aseq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,501,643 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:59 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 9,200 | $3.85 | $35,420.00 |
DisclosureSEC source: 0001104659-25-116084 · tm2532217-1_4aseq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,501,228 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:59 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 1,489 | $4.13 | $6,149.57 |
DisclosureSEC source: 0001104659-25-116084 · tm2532217-1_4aseq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,492,028 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 17:26 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 28,096 | $4.15 | $116,598.40 |
DisclosureSEC source: 0001104659-25-115801 · tm2532176-1_4seq1.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,519,739 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 17:26 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 415 | $4.14 | $1,718.10 |
DisclosureSEC source: 0001104659-25-115801 · tm2532176-1_4seq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,491,643 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 17:26 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 9,200 | $3.85 | $35,420.00 |
DisclosureSEC source: 0001104659-25-115801 · tm2532176-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,491,228 Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 17:26 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 1,489 | $4.13 | $6,149.57 |
DisclosureSEC source: 0001104659-25-115801 · tm2532176-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,482,028 Read SEC document |
| November 21, 2025 Filed Nov 22, 2025 00:57 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 10,000 | $3.50 | $35,000.00 |
DisclosureSEC source: 0001104659-25-115090 · tm2531989-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,490,539 Read SEC document |
| November 21, 2025 Filed Nov 22, 2025 00:57 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 10,000 | $3.49 | $34,900.00 |
DisclosureSEC source: 0001104659-25-115090 · tm2531989-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,480,539 Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 12:44 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 15,000 | $2.11 | $31,650.00 |
DisclosureSEC source: 0001104659-25-113459 · tm2531527-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,470,539 Read SEC document |
| October 28, 2025 Filed Nov 12, 2025 14:18 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | PurchaseCommon Stock | 975,610 | $2.05 | $2,000,000.50 |
DisclosureSEC source: 0001104659-25-109905 · tm2527472-2_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,455,539 Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,000 | $2.30 | $11,500.00 |
DisclosureSEC source: 0001104659-25-087077 · tm2525175-1_4seq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,929 Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,000 | $2.29 | $11,450.00 |
DisclosureSEC source: 0001104659-25-087077 · tm2525175-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,474,929 Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,000 | $2.28 | $11,400.00 |
DisclosureSEC source: 0001104659-25-087077 · tm2525175-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,469,929 Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:20 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 1,100 | $2.57 | $2,827.00 |
DisclosureSEC source: 0001104659-25-080981 · tm2523925-1_4seq1.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,464,929 Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:20 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,545 | $2.58 | $14,306.10 |
DisclosureSEC source: 0001104659-25-080981 · tm2523925-1_4seq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,463,829 Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:20 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,283 | $2.59 | $13,682.97 |
DisclosureSEC source: 0001104659-25-080981 · tm2523925-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458,284 Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:20 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 6,717 | $2.60 | $17,464.20 |
DisclosureSEC source: 0001104659-25-080981 · tm2523925-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,453,001 Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:28 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 1 | $2.83 | $2.83 |
DisclosureSEC source: 0001104659-25-059897 · tm2518124-1_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446,284 Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 20:28 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 25,000 | $2.80 | $70,000.00 |
DisclosureSEC source: 0001104659-25-059897 · tm2518124-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,446,283 Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:35 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 5,000 | $2.43 | $12,150.00 |
DisclosureSEC source: 0001104659-25-055487 · tm2516868-1_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,421,283 Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 19:32 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 164,745 | $6.07 | $1,000,002.15 |
DisclosureSEC source: 0001104659-23-120304 · tm2331305-5_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · The 2018 Jane and Michael Hoffman Descendants Trust Disclosed balance after: 224,222 F1 · ownership.nature: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:24 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 163,880 | $6.10 | $999,668.00 |
DisclosureSEC source: 0001104659-23-120764 · tm2331305-9_4aseq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · The 2018 Jane and Michael Hoffman Descendants Trust Disclosed balance after: 223,357 F1 · ownership.nature: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. Read SEC document |
| November 17, 2023 Filed Jul 3, 2024 21:16 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 29,600 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001104659-24-077833 · tm2417696-2_4seq1.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires 2033-11-17 F1 · security: On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. F2 · derivative.exercise_date: The stock option shall vest immediately upon grant date. Read SEC document |
| April 07, 2023 Filed Apr 12, 2023 01:06 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantCommon Stock | 59,477 | $12.61 | $750,004.97 |
DisclosureSEC source: 0001104659-23-044204 · tm2312464-3_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · The 2018 Jane and Michael Hoffman Descendants Trust Disclosed balance after: 59,477 F1 · ownership.nature: The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 22:38 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 6,820 | $0.00 Strike: $13.17 | $0.00 |
DisclosureSEC source: 0001104659-23-005476 · tm234043-2_4seq1.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820 Underlying: Common Stock · 6,820 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option shall vest in eight consecutive equal quarterly installments each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionStock Option (right to buy) · Derivative | 7,142 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · derivative · entry 7 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,142 shares Expires 2028-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · derivative · entry 6 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2030-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Tax withholdingCommon Stock | 90 | $19.78 | $1,780.20 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416,283 F2 · shares: Reflects 90 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $0.25 per share to fund the cashless exercise of 7,142 options. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionCommon Stock | 7,142 | $0.25 | $1,785.50 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · nonDerivative · entry 3 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Tax withholdingCommon Stock | 6,658 | $19.78 | $131,695.24 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,409,231 F1 · shares: Reflects 6,658 shares withheld by issuer at the market price of $19.78 per share less an exercise price of $4.39 per share to fund the cashless exercise of 30,000 options. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | Exercise / conversionCommon Stock | 30,000 | $4.39 | $131,700.00 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,415,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:41 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0001104659-22-001638 · tm221949-2_4seq1.xml · derivative · entry 5 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: The stock option shall vest in eight consecutive quarterly installments of 1,125 shares each on the 3rd day of April, July, October and January of each year, commencing April 3, 2022, and continuing through January 3, 2024. Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 22:26 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $102.85 | $0.00 |
DisclosureSEC source: 0001104659-21-090742 · tm2121908-2_4seq1.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-07-07 F1 · derivative.exercise_date: The stock option shall vest in eight substantially equal quarterly installments beginning October 7, 2021, provided that the reporting person continues to serve as a director of the issuer on the applicable vesting date. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:42 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 1,876 | $0.27 | $510.08 |
DisclosureSEC source: 0001179110-20-009437 · edgar.xml · nonDerivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 20:42 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | SaleCommon Stock | 182,492 | $0.27 | $49,619.57 |
DisclosureSEC source: 0001179110-20-009437 · edgar.xml · nonDerivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Michael and Jane Hoffman 2013 Descendants Trust Disclosed balance after: 21,919 F1 · ownership.nature: These shares are held for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:29 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 125,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008193 · edgar.xml · derivative · entry 1 Hoffman Michael B · CIK 0001290208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest 100% on the first anniversary of the grant date. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:30 UTC Amendment | Annovis Bio, Inc. ANVS · Entity 7001 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001104659-20-081235 · a4a.xml · derivative · entry 2 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-07-01 Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionConvertible Note · Derivative | 55,884 | $4.80 | $268,243.20 |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · derivative · entry 7 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,884 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F4 · shares: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F4 · derivative.exercise_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). F4 · derivative.expiration_date: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A Preferred Stock · Derivative | 1,593,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · derivative · entry 6 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,137,942 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F3 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F3 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionSeries A-1 Preferred Stock · Derivative | 222,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · derivative · entry 5 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 158,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.exercise_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. F2 · derivative.expiration_date: Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 11:05 UTC | Annovis Bio, Inc. ANVS · Entity 7001 | ConversionCommon Stock | 55,884 | $4.80 | $268,243.20 |
DisclosureSEC source: 0001104659-20-010943 · a4.xml · nonDerivative · entry 4 Hoffman Michael B · CIK 0001290208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.